<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256047</url>
  </required_header>
  <id_info>
    <org_study_id>furukawa2009-2</org_study_id>
    <nct_id>NCT01256047</nct_id>
  </id_info>
  <brief_title>Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy</brief_title>
  <official_title>Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiba University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiba University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether preoperative immunonutrition is effective
      on infectious complication and Th1/Th2 differentiation in patients with major hepatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators reported that preoperative immunonutrition improve the incidence of
      postoperative infectious complication in patients after hepatectomy, and modulation of
      Th1/Th2 differentiation may play important roles in this effect.

      Object of this study is to investigate the effects of preoperative immunonutrition on
      incidence of postoperative infectious complication, and Th1/Th2 balance after hepatectomy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative infectious complication</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma IL-6, CRP, Th1/Th2 balance</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bile Duct Cancer</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>preoperative immunonutrition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>ordinary diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral IMPACT</intervention_name>
    <description>oral supplement for 5 days(1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA</description>
    <arm_group_label>group A</arm_group_label>
    <other_name>Oral IMPACT; Ajinomoto Pharma Co., Ltd, Tokyo, Japan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hepatectomy

        Exclusion Criteria:

          -  age younger than 18 years

          -  ongoing infection

          -  gastrointestinal obstruction

          -  respiratory dysfunction

          -  cardiac dysfunction

          -  hepatic dysfunction

          -  renal failure

          -  history of recent immunosuppressive or immunological disease

          -  preoperative evidence of widespread metastatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katsunori Furukawa, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chiba University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katsunori Furukawa, MD</last_name>
    <phone>+81-43-222-7171</phone>
    <phone_ext>72235</phone_ext>
    <email>k-furukawa@umin.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Toshiaki Aida, MD</last_name>
    <phone>+81-43-222-7171</phone>
    <phone_ext>72236</phone_ext>
    <email>aiaida@aol.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chiba University</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katsunori Furukawa, MD</last_name>
      <phone>+81-43-222-7171</phone>
      <phone_ext>72235</phone_ext>
      <email>k-furukawa@umin.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Toshiaki Aida, MD</last_name>
      <phone>+81-43-222-7171</phone>
      <phone_ext>72236</phone_ext>
      <email>aiaida@aol.com</email>
    </contact_backup>
    <investigator>
      <last_name>Katsunori Furukawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2010</study_first_posted>
  <last_update_submitted>January 28, 2014</last_update_submitted>
  <last_update_submitted_qc>January 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chiba University</investigator_affiliation>
    <investigator_full_name>Katsunori Furukawa</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>immunonutrition</keyword>
  <keyword>hepatectomy</keyword>
  <keyword>Th1</keyword>
  <keyword>Th2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

